Zacks.com on MSN2d
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?
Recursion Pharmaceuticals (RXRX) was a big mover last session on higher-than-average trading volume. The latest trend in ...
Zacks.com on MSN1d
Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $8.50, indicating a +1.92% shift from the previous trading day.
Recursion Pharmaceuticals’ (RXRX) AI Approach to Drug Discovery Shows Progress
Recursion Pharmaceuticals (RXRX) is a clinical-stage biotechnology company utilizing artificial intelligence to expedite drug ...
Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off
Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced solid tumors with positive interim phase 1 data. Read more here.
Hosted on MSN1d
Biotechs on the Brink: 2 Stocks With Huge Potential
Investors know the biotech industry is a waiting game—smaller companies in this space often work to secure the funding to ...
Investing5d
Recursion Pharmaceuticals Inc (RXRX)
Christopher Gibson, CEO of Recursion Pharmaceuticals Inc. (NASDAQ:RXRX), recently sold 40,000 shares of Class A common stock over two days, according to a filing with the... ByInvesting.com ...
Seeking Alpha5d
RXRX Stock Split History
We currently have no RXRX Stock Split History on this stock.